Download PDF

1. Company Snapshot

1.a. Company Description

iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States.It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias.The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data.


It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products.The company was incorporated in 2006 and is headquartered in San Francisco, California.

Show Full description

1.b. Last Insights on IRTC

The recent performance of iRhythm Technologies, Inc. is negatively driven by reimbursement pressure and rising competition. Despite strong volume growth, AI-driven innovation, and primary care expansion, the company faces challenges from reimbursement pressure, which may impact its revenue and profitability. Additionally, the increasing competition in the market may erode its market share and revenue growth.

1.c. Company Highlights

2. iRhythm's Q4 2025 Earnings: A Strong Finish to a Year of Growth

iRhythm Holdings, Inc. reported a strong fourth quarter, with revenue reaching $208.9 million, representing a 27.1% year-over-year growth. The company's full-year revenue was $747.1 million, a 26.2% increase from the previous year. Adjusted EBITDA margin meaningfully exceeded the 15% goal, and the company achieved positive free cash flow for the first time in its history. The actual EPS came out at $0.29, beating estimates of $0.02.

Publication Date: Feb -24

📋 Highlights

Revenue Growth and Margin Expansion

The company's revenue growth was driven by its leadership in long-term continuous monitoring, with a nearly 72% share in a segment growing in the high teens. iRhythm's EHR integration strategy has been successful, with over half of its volume flowing through EHR integrated accounts. As Daniel Wilson noted, the company expects incremental improvement in gross margin, with a range of 80 to 100 basis points of improvement relative to 2025.

Valuation and Growth Expectations

iRhythm's valuation metrics indicate a premium price, with a P/S Ratio of 6.09 and an EV/EBITDA of -597.06. Analysts estimate next year's revenue growth at 15.9%. The company's ROE is -38.33%, and the ROIC is -5.76%. The current valuation suggests that the market is pricing in significant growth expectations, and the company's ability to deliver on its guidance will be crucial in determining its stock performance.

Product Innovation and International Expansion

iRhythm advanced its predictive AI capabilities in 2025, with early pilots showing over 85% accuracy in pre-identifying patients with clinically relevant arrhythmias. The company is excited about its next-gen MCT device, currently under FDA review, which is expected to be released in the first half of 2027. Internationally, iRhythm is commercial in the U.K., select EU markets, and Japan, with a focus on disciplined execution, evidence generation, and reimbursement progression.

Guidance and Outlook

The company expects revenue to be in the range of $870 million to $880 million in 2026, representing 16% to 18% year-over-year growth. iRhythm anticipates adjusted EBITDA margin to expand meaningfully to 11.5% to 12.5% of revenue in 2026. The company's guidance suggests a continued focus on volume-led growth, expanding profitability, and investing in product and international growth.

3. NewsRoom

Card image cap

Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm

Apr -09

Source: prnewswire.com

Card image cap

Head-To-Head Survey: MSP Recovery (NASDAQ:MSPR) & iRhythm Technologies (NASDAQ:IRTC)

Apr -06

Source: defenseworld.net

Card image cap

Here's Why You Should Retain IRTC Stock in Your Portfolio for Now

Apr -01

Source:

Card image cap

Data presented at ACC.26 further demonstrate the benefits of iRhythm's Zio® ambulatory ECG portfolio across multiple patient populations as company launches new digital education platform

Mar -30

Source: globenewswire.com

Card image cap

Assenagon Asset Management S.A. Grows Stock Position in iRhythm Technologies $IRTC

Mar -26

Source: defenseworld.net

Card image cap

This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund

Mar -20

Source: fool.com

Card image cap

Cinctive Capital Management LP Takes $4.82 Million Position in iRhythm Technologies $IRTC

Mar -16

Source: defenseworld.net

Card image cap

iRhythm Holdings Appoints Jason Patten to its Board of Directors

Mar -12

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (13.97%)

6. Segments

Contracted Third-party Payors

Expected Growth: 14.0%

iRhythm Technologies, Inc.'s 14.0% growth in Contracted Third-party Payors is driven by increasing adoption of Zio XT, a wearable cardiac monitoring device, among healthcare providers and patients. Expanding payer coverage, growing demand for remote patient monitoring, and strategic partnerships with leading health systems also contribute to this growth.

Centers for Medicare & Medicaid

Expected Growth: 15.0%

iRhythm Technologies, Inc.'s 15.0% growth from Centers for Medicare & Medicaid is driven by increasing adoption of Zio XT, a wearable cardiac monitoring device, and expanding reimbursement coverage. Additionally, growing demand for remote patient monitoring and telehealth services, as well as increasing prevalence of atrial fibrillation, contribute to the segment's growth.

Healthcare Institutions

Expected Growth: 13.0%

iRhythm Technologies, Inc.'s 13.0% growth in Healthcare Institutions is driven by increasing adoption of AI-powered cardiac diagnosis, rising demand for remote patient monitoring, and growing need for accurate arrhythmia detection. Additionally, expansion into new markets, strategic partnerships, and investments in digital health technologies are contributing to the company's growth momentum.

Non-contracted Third-party Payors

Expected Growth: 12.0%

The 12.0% growth in Non-contracted Third-party Payors from iRhythm Technologies, Inc. is driven by increasing adoption of Zio XT, expansion into new markets, and growing demand for remote cardiac monitoring solutions. Additionally, favorable reimbursement trends and strategic partnerships contribute to this growth.

7. Detailed Products

Zio XT

A single-use, patch-type wearable cardiac monitor that records and stores ECG data for up to 14 days.

Zio AT

A single-use, patch-type wearable cardiac monitor that records and stores ECG data for up to 2 weeks.

Zio Rhythm Management

A comprehensive rhythm management solution that includes the Zio XT or Zio AT patch, data analysis, and reporting.

Zio Analytics Platform

A cloud-based platform that provides data analysis, reporting, and insights for cardiac rhythm data.

8. iRhythm Technologies, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

iRhythm Technologies, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the evolving nature of the healthcare industry.

Bargaining Power Of Customers

iRhythm Technologies, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are critical to patient care, making it difficult for customers to negotiate prices.

Bargaining Power Of Suppliers

iRhythm Technologies, Inc. relies on a few key suppliers for critical components, which gives them some bargaining power. However, the company's strong relationships with suppliers and its ability to negotiate contracts mitigate this risk.

Threat Of New Entrants

The medical device industry has high barriers to entry, including regulatory hurdles and significant research and development investments. This makes it difficult for new entrants to compete with iRhythm Technologies, Inc.

Intensity Of Rivalry

The medical device industry is highly competitive, with several established players competing for market share. iRhythm Technologies, Inc. faces intense competition from companies like Medtronic and Abbott Laboratories.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 19.26%
Debt Cost 3.95%
Equity Weight 80.74%
Equity Cost 10.52%
WACC 9.25%
Leverage 23.85%

11. Quality Control: iRhythm Technologies, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Penumbra

A-Score: 4.8/10

Value: 0.4

Growth: 8.2

Quality: 7.3

Yield: 0.0

Momentum: 8.0

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
CONMED

A-Score: 4.8/10

Value: 7.4

Growth: 6.4

Quality: 5.9

Yield: 3.0

Momentum: 1.0

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
Inari Medical

A-Score: 4.8/10

Value: 4.0

Growth: 8.0

Quality: 4.8

Yield: 0.0

Momentum: 9.5

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
iRhythm Technologies

A-Score: 4.7/10

Value: 4.2

Growth: 6.1

Quality: 3.2

Yield: 0.0

Momentum: 10.0

Volatility: 4.7

1-Year Total Return ->

View Full Report
Stock-Card
Bio-Rad

A-Score: 4.0/10

Value: 6.5

Growth: 2.3

Quality: 4.7

Yield: 0.0

Momentum: 5.0

Volatility: 5.3

1-Year Total Return ->

View Full Report
Stock-Card
Align Technology

A-Score: 3.6/10

Value: 3.6

Growth: 5.3

Quality: 7.2

Yield: 0.0

Momentum: 2.0

Volatility: 3.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

124.41$

Current Price

124.41$

Potential

-0.00%

Expected Cash-Flows